Multiple sclerosis (MS) is a demyelinating disease of presumed T cell autoimmunity against self myelin. We hypothesized that if myelin-reactive T cells are associated with the disease processes, they may undergo activation and expansion during acute exacerbation. In this study, we examined the precursor frequency, epitope recognition and cytokine 
Introduction
Multiple sclerosis (MS) is a demyelinating disease of the protein (MBP), proteolipid protein (PLP) (10) and myelin oligodendrocyte glycoprotein (MOG) (11, 12) , that have been central nervous system characterized pathologically by focal infiltration of inflammatory cells in the white matter (1). There implicated in the pathogenesis of MS for their ability to induce experimental autoimmune encephalomyelitis (EAE), an animal are two basic clinical forms of MS, relapsing/remitting and chronic progressive MS, which exhibit distinct features (2-4).
model for MS (13, 14) . It has been demonstrated that only a limited number of epitopes on these myelin antigens are The relapsing-remitting form of MS is characterized clinically by episodic worsening (exacerbation) and recovery of encephalitogenic and associated with the induction of EAE (14) . T cells recognizing a variety of epitopes, including the neurologic functions (remission). Although the etiology and pathogenesis of MS is unknown, there is increasing evidence encephalitogenic epitopes, are present as part of the normal T cell repertoire, exhibiting a diverse clonal distribution in suggesting that the T cell responses to myelin antigens may play an important role in the disease processes (5-9). There naive animals (15). It has been demonstrated that the diversity in clonal distribution of MBP-reactive T cells is lost in EAE. are at least three candidate myelin antigens, i.e. myelin basic Immunization with the whole MBP induces selective activation supplemented with L-glutamine, sodium pyruvate, non-essential amino acids, 10 mM HEPES buffer (Gibco), 10% (v/v) FBS and expansion of encephalitogenic T cell populations, resulting in a skewed pattern of clonal distribution toward (Gibco) and 1% penicillin/streptomycin (Gibco). Recombinant human IL-2 (rIL-2) was purchased from Boehringer Mannheim the encephalitogenic epitopes (16) . This clonal distribution pattern characteristic of EAE returns to its pre-clinical diversity (Indianapolis, IN). A panel of overlapping peptides of human MBP (residues when animals recover from the disease.
Substantial T cell responses to all three myelin antigens 83-99 and 151-170) was synthesized by the Merrified solidphase method and purified by HPLC (courtesy of Dr Stefen have been reported in patients with MS (7, (17) (18) (19) (20) (21) (22) (23) . In a recent study, the frequency of T cells recognizing an immunoBoheme, Neurocrine Biosciences). Two peptides of human PLP (residues 30-49 and 180-199) and a MOG peptide dominant epitope was found to be 1/300-1/1000 in the blood of patients with MS (24). There is preliminary evidence that (residues 41-60) were synthesized by Chiron (San Diego, CA). The purity of all peptides used in this study was Ͼ95%. the TCR-CDR3 sequence of MBP-reactive T cells derived from MS patients was present in post-mortem MS lesions
Patient selection and clinical criteria (25). However, these myelin-reactive T cells can also be isolated from normal individuals (7, 9, 17, 18, 26, 27) , suggesting
Fourteen patients with clinically definite relapsing-remitting MS (six males and eight females) were recruited in the that myelin-reactive T cells are part of the normal T cell repertoire. Furthermore, the T cell responses to these study. The diagnosis was made based on standard clinical manifestations and laboratory studies confirmed by magnetic candidate myelin antigens are considerably heterogeneous in the epitope recognition among different individuals with resonance imaging (3,4). All patients were characterized as having relapsing-remitting MS for Ͼ2 years. The patients were MS (7) (8) (9) (28) (29) (30) (31) . Nevertheless, some regions of MBP and PLP, including residues 83-99 and 151-170 for MBP and not treated with immunosuppressive or immunomodulatory agents for at least 2 months prior to entry. Patients were residues 30-49 and 181-199 for PLP, are preferentially recognized in patients with MS (6, 7, 10, 19, 32) , and the recruited at the time of an acute exacerbation according to the clinical criteria routinely used in MS studies (37, 38) . Briefly, immunodominant properties of residues 83-99 and 151-170 of MBP are associated with their high binding affinity to HLAan acute exacerbation was defined as the appearance of new symptoms or worsening of old symptoms consistent with DR2 (33) . One of the important discrepancies between myelinreactive T cells in MS patients and those in normal individuals MS with objective signs sufficiently severe to produce a deterioration of 1 point on expanded disability scale score is the activation state of the T cells. MBP-reactive T cells are found to undergo in vivo activation and clonal expansion in (EDSS). The symptoms lasted for at least 24 h, which were not attributable to other medical conditions of the patients. patients with MS, as opposed to healthy individuals (6,34,35).
It was hypothesized that if myelin-reactive T cells were Informed consent was obtained from the patients after explaining the experimental procedures. The protocol was associated with acute exacerbation, they would exhibit characteristic changes in the precursor frequency and the approved by the Institutional Human Subjects Committee at Baylor College of Medicine. Seven asymptomatic healthy functional properties during exacerbation as a result of selective in vivo activation and expansion. This study was individuals were recruited as control subjects. Blood specimens were obtained from patients at the time undertaken to address these issues by analyzing the precursor frequency, epitope recognition and cytokine profile of acute exacerbation within 2-4 days following the onset of new or worsened neurologic deficits and before any treatment of myelin-reactive T cells during acute exacerbation, and comparing them with those occurring during remission in the was initiated. Sixty percent of the patients received a 3-day course of methylprednisolone (1 g, i.v. daily) and the remaining same patients. Seven healthy individuals were examined in parallel. The study revealed that aberrant T cell responses to patients opted to defer the treatment in fear of side effects. No other immunosuppressive agents were used. Blood the candidate myelin antigens correlated with acute exacerbation in MS patients. The myelin-reactive T cells occurred at specimens corresponding to remission were obtained 2-3 months following the onset of acute exacerbation when all increased precursor frequency in MS patients during acute exacerbation, and exhibited distinct functional properties and patients returned to their baseline neurologic functions as determined clinically by a neurologist. epitope recognition as compared to those obtained from the same patients during remission. The findings described in HLA-DR2 typing this study provide new insights into the potential role of myelinreactive T cells in the pathogenesis of MS and encourage Total cellular RNA was extracted from peripheral blood mononuclear cell (PBMC) specimens using the RNeasy mini kit further investigation to identify myelin-reactive T cells associated with disease activity in MS.
(Qiagen, Santa Clarita, CA). RNA was reverse transcribed to first-strand complementary DNA (cDNA) using an oligo(dT) primer and the superscript pre-amplification system (Gibco, Methods Gaithersburg, MD). cDNA was amplified by PCR using oligonucleotide primers specific for DRB1*1501 as described Reagents and peptides elsewhere (39) . Briefly, 1 µl cDNA was added into the following amplification mixture: 5 µl of 10ϫPCR buffer II (100 mM TrisHuman MBP was purified from the white matter of the human brain by the method previously described by Deibler et al. HCl, pH 8.3, 500 mM KCl), 3 µl of 25 mM magnesium chloride, 1 µl of 10 mM dNTP mix, 0.3 µl of Taq polymerase (5 U/µl) (36) . Media used for cell culture were AIM-V serum-free medium (Gibco/BRL, Grand Island, NY), and RPMI 1640 (AmpliTaq Gold; Perkin-Elmer, Norwalk, CT), 10 pmol of a specific primer as the forward primer and 10 pmol of a peptides were used at a concentration of 10 µg/ml. Hen egg
lysozyme (HEL) was used as a control antigen (40 µg/ml).
The total number of wells for each peptide varied from 24 to
32. Seven days later, the cultures were re-stimulated with
corresponding peptides in the presence of 10 5 irradiated
(6000 rad) autologous PBMC as a source of antigen-presenting cells. rIL-2 (50 IU/ml) was added 48 h later to RR, relapsing-remitting MS. NS, normal subjects. All blood supplement T cell growth. Two weeks later, each culture specimens were typed for the DRB1*1501 status (ϩ or -) by PCR (see Methods) was examined for specific proliferation in response to the corresponding peptide in a proliferation assay. Briefly, each well was split into four aliquots and cultured in duplicate with 10 5 irradiated autologous PBMC in the presence and the and added in duplicate wells. Plates were incubated at 4°C absence of the corresponding peptide. Culture supernatants overnight and subsequently washed 5 times with PBS/T. were collected after 48 h for cytokine ELISA. The remaining Then 100 µl of the matched biotinylated detecting antibody cultures were maintained for an additional 24 h and pulsed (0.5 µg/ml for IL-4 and IL-10 and 1 µg/ml for IFN-γ and TNF-α; subsequently with [ 3 H]thymidine (Amersham, Arlington PharMingen) were added to each well and incubated at Heights, IL) at 1 µCi/well during the last 16 h of culture.
room temperature for 2 h. After washing, avidin-conjugated Cells were then harvested using an automated cell harvester horseradish peroxidase (1:5000 dilution) was added and (Tomtec, Orange, CT) and [ 3 H]thymidine incorporation was plates were incubated for 1 h. Plates were then washed and measured in a β-counter.
3,3Ј,5,5Ј-tetramethylbenzidine/1.2 mM H 2 O 2 in citrate buffer A T cell line was defined as specific for MBP or a peptide (pH 5.0) was used as a substrate for color development. The when c.p.m. Ͼ 1000 and exceeded the reference c.p.m. (in reaction was stopped by adding 1N HCl. Optical density was the absence of the antigen) by at least 3 times. The frequency measured at 450 nm by using an ELISA reader (BioRad, of peptide-reactive T cells was then estimated by dividing Hercules, CA) and cytokine concentrations were quantitated the number of positive wells by the total number of PBMC by Microplate computer software (BioRad) using a double seeded in the initial culture (6,40). The same calculation was eight-point standard curve. The detection limit of the assays used consistently in all experiments.
was Ͻ30 pg/ml for all cytokines.
Cytokine quantification by ELISA Statistical analysis Cytokines were determined quantitatively in culture A Student's t-test (for normally distributed variables) and the supernatants using ELISA kits obtained from PharMingen Mann-Whitney rank-sum test (for non-normally distributed (San Diego, CA). The kits were used according to the manufacvariables) was used for data analysis. P Ͻ 0.05 was turer's instructions. Microtiter plates (96-wells, Maxisorp; considered statistically significant. Nunc, Roskilde, Denmark) were coated overnight at 4°C with 2 µg/well of a purified mouse capturing mAb to human cytokine [IL-4, IL-10, tumor necrosis factor (TNF)-α and Results IFN-γ] (PharMingen, San Diego, CA) in 100 µl of a carbonate
The estimated frequency of myelin-reactive T cells in the buffer (100 mM, pH 9.5). Plates were washed with PBS blood of MS patients and control subjects during acute (pH 7.0) containing 0.05% Tween 20 (PBS/T). Non-specific exacerbation and remission binding sites were saturated with 10 % (w/v) FBS in PBS (FBS/PBS) for 1 h and washed subsequently with PBS/T.
Fourteen patients with definite relapsing-remitting MS (age range 33-66) were included in this study. The clinical Supernatants and cytokine standards were diluted with PBS Table 1 . The mean EDSS of the patient group was 4.5 (range 2.5-6.0). To address whether acute MBP83-99 and 0.38ϫ10 -6 for MBP151-170, during remission. Similarly, as illustrated in Fig. 1(B and C) , the frequency of T exacerbation is associated with activation and expansion of myelin-reactive T cells, the precursor frequency of myelincells recognizing the PLP and MOG peptides was also elevated during acute exacerbation (1.78ϫ10 -6 for PLP30-49, reactive T cells was analyzed at two time points, corresponding to acute exacerbation (2-4 days following acute onset 1.97ϫ10 -6 for PLP180-199 and 1.99ϫ10 -6 for MOG41-60) and decreased significantly during remission (0.45ϫ10 -6 for of exacerbation) and remission (2-3 months after acute exacerbation). A group of seven healthy volunteers (age PLP30-49, 0.43ϫ10 -6 for PLP180-199 and 0.53ϫ10 -6 for MOG41-60) in the same patients. In contrast, the frequency range 26-56) was examined in the same experimental setting at two time points. The myelin antigens used in this study of T cells specific for HEL (a control antigen) did not differ significantly between acute exacerbation and remission included the whole human MBP, two peptides of MBP (residues 83-99 and 151-170), two peptides of human PLP (mean frequency 0.9ϫ10 -6 versus 0.8ϫ10 -6 ) in eight patients examined. There was no significant correlation between the (residues 31-49 and 180-199) and a MOG peptide (residues 41-60). These myelin peptides were previously shown to expression of DRB1*1501 and the frequency of T cells recognizing any of the myelin antigens in this group of patients. represent immunodominant regions of the candidate myelin antigens in patients with MS (6,7,10,19,22,23). Some of these
We then examined whether myelin-reactive T cells would undergo a similar change in the precursor frequency in peptides are encephalitogenic in rodents (14, 41) .
As shown in Fig. 1(A) , T cells recognizing MBP and the healthy individuals. As shown in Fig. 2 , the frequency of T cells reactive to the myelin antigens was generally lower immunodominant myelin peptides occurred at an increased frequency at the time of acute exacerbation, and the T cell (Ͻ1.0ϫ10 -6 ) than that in MS patients during acute exacerbation and was highly comparable to that seen in the MS frequency declined substantially during remission in patients with relapsing-remitting MS (P Ͻ 0.05). The mean frequency patients during remission. No statistical difference in the precursor frequency of myelin-reactive T cells was detected of T cells was 1.55ϫ10 -6 for the whole MBP molecule, 1.80ϫ10 -6 for MBP83-99 and 2.74ϫ10 -6 for MBP151-170, between the two time points (2-3 months apart), even though Next, we examined whether myelin-reactive T cells occurring during acute exacerbation would exhibit a different cytokine The combined use of the whole MBP molecule containing all potential epitopes with the two immunodominant MBP profile from those obtained from the same patients during remission. To this end, a panel of 650 short-term myelinpeptides allowed us to discern whether shifts occurred between the immunodominant epitopes and potential reactive T cell lines, including 402 lines obtained during acute exacerbation and 248 lines obtained during remission, were epitopes other than those within the 83-99 and 151-170 regions of MBP. As illustrated in Fig. 3(a) , during acute assayed for the production of both T h 1 (IFN-γ, TNF-α) and T h 2 (IL-4, IL-10) cytokines. The culture supernatants were exacerbation, the T cell reactivity to MBP was predominantly directed at the immunodominant regions, with the 151-170 collected 48 h after the T cell lines were challenged with corresponding antigens and measured for the absolute conregion being the most dominant in the majority of the patients, while the reactivity to the MBP molecule was less dominant.
centration of the cytokines in ELISA. The distribution of the epitope specificity of the two panels of myelin-reactive T cell This pattern of epitope recognition appeared to shift toward the whole MBP molecule among MBP-reactive T cells occurring lines examined for the cytokine profile was representative of those shown in Fig. 1 , with the T cell lines specific for during remission (Fig. 3a) . The results suggest that in the case of MBP, the T cell reactivity was focused predominantly the immunodominant myelin peptides being the dominant population in acute exacerbation. The majority of the MBPon the immunodominant regions during acute exacerbation reactive T cell lines obtained during remission were the whole MBP and the 150-170 region was slightly higher during exacerbation than that during remission in MS patients predominantly directed at the whole MBP molecule.
As a group, the myelin-reactive T cell lines obtained during (Table 2 ). The IL-4 production of MS-derived MBP-reactive T cells was lower than that derived from healthy individuals. acute exacerbation produced significantly increased amounts of IFN-γ and TNF-α as compared to these derived from the The production of IL-10 was not changed in any of the panels of myelin-reactive T cells. Furthermore, a panel of 85 HELsame patients during remission as well as healthy individuals. The production of IL-4 in MBP-reactive T cells recognizing specific T cell lines derived from MS patients during acute The observed change in the precursor frequency of myelinreactive T cells is unlikely attributable to the inhibitory effect 107 Ϯ 13 pg/ml for IL-4, 332 Ϯ 37 versus 398 Ϯ 45 pg/ml for TNF-α and 111 Ϯ 6 versus 108 Ϯ 14 pg/ml for IFN-γ of the steroids given to some of the patients as a standard treatment for acute exacerbation since the treatment was very respectively in myelin-reactive T cell lines derived during acute exacerbation and remission. However, the changes in brief (a 3-day course) and the subsequent frequency analysis was 2-3 months following the treatment. In this study, the the cytokine concentrations between the two time points were not statistically significant (P Ͼ 0.05).
wash-out period for steroids treatment was significantly longer than that routinely used in the MS trials (30 days) (38, 42, 37) . Furthermore, in patients who deferred the treatment for various Discussion reasons, the precursor frequency of myelin-reactive T cells was similar to that seen in the treated patients. Selective The role of myelin-reactive T cells in the pathogenesis of MS remains speculative despite extensive research effort in activation and expansion of myelin-reactive T cells during acute exacerbation is contrasted by the observation that T this area (5- 8, 22, 23) . One of the approaches to defining the potential role of myelin-reactive T cells is to examine the cells recognizing a control antigen (HEL) did not undergo a similar change in the same patients between two time points. precursor frequency in patients with MS, which provides an indication for selective in vivo activation and expansion of It is likely that episodic activation and expansion of myelinreactive T cells may be related to triggering events, such as some subsets of myelin-reactive T cells. To date, the results accumulated from studies involving randomly recruited clinically overt or subtle viral infection (31), correlating with the relapsing-remitting features of the disease. For example, patients with chronic progressive and relapsing-remitting MS indicate that T cells recognizing MBP and PLP occur at a several infectious agents, including human herpes virus-6 (HHV-6), have been found to correlate with clinical exacerbaslightly higher or similar precursor frequency in MS patients as compared to control subjects (7, 18, 27) . In this study, tion in relapsing-remitting MS (43) . Activation and expansion of myelin-reactive T cells may in turn trigger immune regulation we took a different approach by analyzing the precursor frequency and functional properties of myelin-reactive T cells through various peripheral regulatory mechanisms (e.g. apoptosis and clonal anergy), which down-regulate activated occurring during acute exacerbation and remission. We demonstrated for the first time that a high precursor frequency myelin-reactive T cells shortly after exacerbation (10, 44, 45) . However, in the absence of the TCR V gene analysis, it is not of myelin-reactive T cells correlated with acute exacerbation in relapsing-remitting MS. The precursor frequency of myelinclear whether the increased precursor frequency reflects the expansion of the existing myelin-reactive T cell populations reactive T cells detected during acute exacerbation is also higher than that reported previously in randomly recruited MS or whether it is attributable to in vivo activation of distinct myelin-reactive T cell subsets. patients (6-8). The increased precursor frequency of T cells correlated with reactivity to the immunodominant peptides
In addition to the increased T cell precursor frequency during acute exacerbation, the T cell responses to the myelin of the candidate myelin antigens, most noticeably the 150-antigens undergo characteristic shift in epitope recognition.
relapsing-remitting MS and these cells exhibit a distinct cytokine profile from those occurring during remission. The It is of interest to note that the C-terminal MBP151-170 peptide represents the most dominant epitope of MBP in the majority findings consistently suggest that myelin-reactive T cells detected in MS patients during remission are similar to those of patients examined during acute exacerbation. The results suggest that there may be selective activation and expansion identified in the normal T cell repertoire in healthy individuals. The study provides critical information for further investigating of T cells recognizing the immunodominant myelin peptides at the time of exacerbation. During remission, the pattern of the potential role of myelin-reactive T cells in MS. For example, it is important to further delineate whether myelin-reactive T epitope recognition shifted largely toward MBP, resembling that found in the normal T cell repertoire in healthy individuals.
cells associated with recurrent exacerbation would express identifiable markers (e.g. TCR V gene usage and CDR3 There are several related issues that need further investigation. First, although the combined use of the whole MBP (as sequence motifs). Furthermore, the findings described here have practical implications in the development of effective a substitute for all potential epitopes) and the two immunodominant peptides of MBP helped to discern shift in the immunotherapy for MS, reinforcing the importance in selecting pathologically relevant myelin-reactive T cells for recognition of the immunodominant regions during acute exacerbation and other epitopes outside these regions specific immunotherapy, such as T cell vaccination and TCR peptide vaccination. In this regard, specific depletion or during remission, it did not distinguish whether the T cell recognition of the whole MBP during remission was directed suppression of the myelin-reactive T cells associated with clinical exacerbation is potentially more efficacious. Conat one or few epitope(s) outside the 83-99 and 151-170 regions or whether it represented diverse responses to a versely, elimination of the 'house-keeping' T cell population representing the normal T cell repertoire is not only ineffective variety of potential epitopes. Further study is needed to clarify the issue using overlapping peptides of the myelin antigens.
and may be harmful because of their potential regulatory functions (e.g. IL-4 and IL-10) that are not well understood at Second, it remains to be determined in future investigations whether activation and expansion of myelin-reactive T cells the present time. is characteristic of relapsing-remitting MS and whether chronic progressive MS patients exhibit a distinct pattern of shift in the precursor frequency of myelin-reactive T cells and theMS patients had already undergone a lengthy clinical course prior to the study. However, epitope spreading among candidate myelin antigens may be detectable in MS if patients Abbreviations are monitored at the early stage of the disease as suggested in recent studies by Tuohy et al. (46, 47) . 
